Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis
Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) as first-line adjunctive therapy in levodopa/DOPA decarboxylase inhibitors-treated Parkinson’s disease (PD) patients…Effects of onabotulinum toxin A on balance and gait in Parkinson’s disease with foot dystonia: A case series study
Objective: To investigate the effectiveness of botulinum toxin (BoNT) in reducing the severity of dystonia and improving gait and balance in Parkinson’s disease (PD) patients…Beta-adrenoreceptor medications and risk of Parkinson’s disease
Objective: To review and analyze the associations between β-adrenoreceptor medications and risk of Parkinson's disease. Background: Distinctive Lewy body mainly composed of α-synuclein is an…Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Objective: This real-world study evaluated opicapone (OPC) 50-mg in a heterogeneous population of Parkinson’s disease (PD) patients treated in clinical practice. Background: OPC proved effective…Pill burden reduction in patients with advanced Parkinson’s disease: Comparative effectiveness of carbidopa/levodopa enteral suspension and Deep brain stimulation
Objective: To compare the real-world impact of initiating carbidopa/levodopa enteral suspension (CLES) or deep brain stimulation (DBS) on reducing pill burden (i.e. total number of…Cardiac Autonomic Dysfunction in Patients with Multiple System Atrophy: A cross-sectional study
Objective: The study aimed to assess cardiac autonomic dysfunction in patients with multiple system atrophy (MSA). Background: MSA is a progressive neurodegenerative disorder with predominant…Cardiac Safety of PBT434, an Inhibitor of Alpha-Synuclein Aggregation for the Treatment of Multiple System Atrophy (MSA)
Objective: Evaluate potential cardiac liability of PBT434 using concentration-response and outlier analyses of ECG and pharmacokinetic (PK) data from a Phase 1 study of PBT434…The severity and distribution of tau pathology distinguish corticobasal degeneration and progressive supranuclear palsy
Objective: To elucidate whether the severity and distribution of tau pathology reflect the clinical presentations in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Background:…Parkinsonism, delayed chorea and dystonia caused by extrapontine myelinolysis
Objective: To describe two case reports of patients with movement disorders due to extrapontine myelinolysis. Background: Central Pontine Myelinolysis (CPM) and Extra pontine myelinolysis (EPM)…Parkinsonism secondary to mercury poisoning in a Colombian population
Objective: To describe the clinical and paraclinical characteristics of patients over 18 years of age who consulted the Neurology service of the University Hospital with…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 149
- Next Page »